Objective: Hormone therapy has been shown to reduce markers of vascular inflammation in postmenopausal women. C-reactive protein (CRP), a marker of generalized inflammation, is raised by oral estradiol therapy (ET). It is not known how sex hormone concentrations relate to the markers of inflammation in postmenopausal women taking or not taking hormone therapy.
I nflammation is a critical process in atherogenesis. The early stages of atherosclerosis involve an inflammatory process consisting of the migration of leukocytes and monocytes into the subendothelium. Adhesion molecules such as soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin mediate the adhesion and migration of leukocytes into the arterial wall. 1 Circulating adhesion molecules are positively associated with levels of atherosclerosis 2 and risk for cardiovascular events. 3 Coronary heart disease is rare in women before menopause compared with men of the same age. The incidence of coronary heart disease in postmenopausal women is significantly higher than that in premenopausal women of the same age, 4 suggesting a cardioprotective effect of endogenous sex hormones, particularly estrogen. In a cross-sectional study, circulating inflammatory markers, including sICAM, VCAM, and E-and Pselectins, were significantly higher in postmenopausal women not taking hormone therapy (HT) compared with premenopausal women, controlling for age and body mass index (BMI). 5 The impact of postmenopausal HT on markers of vascular inflammation such as adhesion molecules and cytokines has been studied by a number of investigators, revealing an overall decrease in vascular inflammation among HT users. 6<8 In contrast, liver-derived C-reactive protein (CRP), a marker of generalized inflammation, 9 increased with oral HT. 10 In postmenopausal women, endogenous or physiological levels of sex hormones differ markedly from the pharmacological levels induced by HT. It is unknown whether serum concentrations of estrogens, androgens, and sex hormoneY binding globulin (SHBG) correlate with markers of inflammation in postmenopausal women or whether such associations differ at physiological and pharmacological levels of sex hormones.
We used data from the Estrogen in the Prevention of Atherosclerosis Trial (EPAT) to evaluate the association of estrogens, androgens, and SHBG at physiological and pharmacological levels with markers of inflammation and proinflammatory factors in postmenopausal women. In EPAT, serum levels of sex hormones, CRP and sICAM-1, low-density lipoprotein (LDL) oxidation, and homocysteine were measured longitudinally for 2 years. To our knowledge, this is the first study to relate both physiological and pharmacological sex hormone concentrations to inflammatory markers and proinflammatory factors longitudinally in the same cohort.
METHODS
The EPAT study design has been described. 11 In brief, EPAT was a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the impact of oral unopposed 17A-estradiol on subclinical atherosclerosis in postmenopausal women who had no clinically evident cardiovascular disease. A total of 222 women were randomized to either placebo or active treatment of oral unopposed micronized 17A-estradiol (1 mg/d). Women were eligible to participate if their estradiol (E 2 ) level was less than 20 pg/mL, LDL-cholesterol level was equal to or greater than 130 mg/dL, and fasting blood glucose level was less than 200 mg/dL and they were not smoking. Randomized participants were followed with clinic visits every month for the first 6 months, then every other month for the remainder of the 2-year trial period. Participants fasted for 8 hours before sample collection. All study participants provided written informed consent, and the study was approved by the institutional review board of the University of Southern California.
Laboratory measurements Hormone assays
Sex hormone concentrations were measured from fasting serum samples drawn at baseline and every 6 months during the trial period and stored at j70-C. Serum levels of androstenedione (A4), dehydroepiandrosterone (DHEA), testosterone, estrone (E 1 ), and E 2 were quantified by validated, previously described radioimmunoassays (RIAs). 12 Before RIAs were performed, steroids were extracted from serum with hexaneYethyl acetate (3:2). A4, DHEA, and testosterone were then separated by Celite column partition chromatography using increasing concentrations of toluene in trimethylpentane. E 1 and E 2 were separated in a similar fashion by use of ethyl acetate in trimethylpentane. SHBG was quantified by direct immunoassay using the Immulite analyzer (Diagnostic Products Corporation, Inglewood, CA). Free testosterone was calculated using total testosterone and SHBG concentrations and an assumed constant for albumin in a validated algorithm. 13 Free E 2 was calculated in a similar manner.
All immunoassay methods were shown to be reliable. Specificity was achieved by using highly specific antisera and/or organic solvent extraction and chromatographic steps before quantification of the analytes. Assay accuracy was established by demonstrating parallelism between measured concentrations of a serially diluted analyte in serum with the corresponding standard curve. Intra-assay and interassay coefficients of variation (CVs) ranged from 4% to 8% and from 8% to 13%, respectively. The sensitivities for the assays of A4, DHEA, testosterone, E 1 , E 2 , and SHBG assay were 30 pg/mL, 0.05 ng/mL, 1.5 ng/dL, 5 pg/mL, 3 pg/mL, and 1 nmol/L, respectively. The sensitivity of an RIA method was determined by the smallest amount of analyte that reduced the number of counts per minute of the radiolabeled analyte at zero mass by 2 SDs.
Inflammatory markers
Inflammatory markers were measured from fasting serum samples drawn at baseline and every 6 months during the trial period and stored at j70-C at the Laboratory for Clinical Biochemistry Research (University of Vermont, Burlington, VT). CRP was measured in fasting blood specimens by a validated high-sensitivity colorimetric competitive immunoassay (CRP antibodies and antigens from Calbiochem, La Jolla, CA). 14 The intra-assay and interassay CVs were 3% and 6%, respectively. sICAM-1 was measured using a commercially available enzyme-linked immunosorbent assay (Parameter Human sICAM-1 Immunoassay; R&D Systems, Minneapolis, MN); intra-assay and interassay CVs were 4.5% and 6.2%, respectively.
In vitro oxidation of LDL
The kinetics of LDL oxidation were analyzed by adding 10 KM CuSO 4 to 200 Kg/mL LDL protein extracted from fresh serum collected in a fasting state. Formation of conjugated dienes was monitored continuously at 234 nm for up to 16 hours using a Beckman DU-650 spectrophotometer equipped with a six position automated sample changer. Three measures of oxidation kinetics were analyzed: (1) the oxidation lag time, which was defined as the interval between the initiation of oxidation and the intercept of the tangent for the slope of the absorbance curve during the propagation phase; (2) the rate of oxidation during the lag time, defined as the initial oxidation rate before the onset of the propagation phase; and (3) the rate of oxidation during the propagation phase (the log rate), defined as the maximal rate of oxidation calculated from the slope of the absorbance curve during the propagation phase.
Homocysteine
Total fasting homocysteine concentrations were measured from stored frozen plasma samples by reverse-phase highperformance liquid chromatography with a C18 column on a Waters high-performance liquid chromatography instrument equipped with a Waters Wisp Automatic Sample Injector System (WISP) attached to a fluorometer. Solutions containing 40 nmol/mL homocysteine and 200 nmol/mL cysteine were used as standards and for column calibration. For quality control, pooled plasma spiked with different quantities of cysteine and homocysteine were used. The CV for this assay was 7.8%.
Statistical analysis
Baseline demographic and clinical characteristics were compared between the treatment groups using Student's t test (for continuous variables) or a W 2 test (for categorical variables). Mean on-trial levels of the sex hormones were compared between E 2 -and placebo-treated groups using t tests for independent samples. Associations of sex hormone concentrations with inflammatory markers and proinflammatory factors were tested using linear regression with generalized estimating equations. The serial measures of inflammatory markers (CRP and sICAM-1) and proinflammatory factors (homocysteine and LDL oxidation) were the dependent variables, and time-dependent measures of sex hormones/SHBG were the primary explanatory variables. Both the outcome and explanatory measures were modeled as continuous variables. Inflammatory markers/proinflammatory factors at a given follow-up time (trial visit) were regressed on the corresponding sex hormone factors measured from the same trial visit, accounting for the within-subject effect. Because age and/or BMI was associated with serum sex hormone and SHBG concentrations as well as sICAM and CRP levels, all models evaluating the association of serum sex hormones and SHBG with inflammatory markers were adjusted for age and BMI.
Separate regression models were fitted for the E 2 -and placebo-treated groups. All analyses used SAS (version 9.1; SAS Institute, Cary, NC); two-sided P values are reported.
RESULTS
Data on markers of inflammation and sex hormones were available for 216 women from a total of 735 trial visits (median [range], 4 [1] [2] [3] [4] [5] per woman). The mean (SD) age of the EPAT participants was 61 (7) years, and most (61%) of the women were non-Hispanic white. Most of the women were overweight, with a mean (SD) BMI of 29 (5) kg/m 2 , and the mean (SD) LDL-cholesterol level was 164 (28) mg/dL. The median (range) levels of inflammatory markers were the following: sICAM, 282 (107-472) ng/mL; CRP, 1.5 (0.37-13.4) mg/L; and homocysteine, 7.4 (4.1-40.2) nmol/mL. The baseline demographic and clinical characteristics were not statistically significantly different between the placebo and E 2 groups (P value for difference for all, 90.30; Table 1 ).
Women treated with oral E 2 (1 mg/d) had significantly higher E 1 , total and free E 2 , and SHBG levels (all P values G .0001; Table 2 ). In contrast, androgens, including free testosterone (P = 0.0001), A4 (P G 0.0001), and DHEA (P G 0.0001), were significantly lower in E 2 -treated compared with placebotreated women. Serum levels of total testosterone did not differ between the two treatment groups (P = 0.72). Among women receiving estradiol therapy (ET), sICAM-1 was significantly inversely associated with E 1 (P = 0.05), total E 2 (P = 0.008), free E 2 (P = 0.02), and SHBG (P = 0.03), adjusted for age and BMI (Table 3) . A significant positive association was observed between sICAM-1 and free testosterone (P = 0.04). Total testosterone, A4, and DHEA were not associated with sICAM-1. None of the sex hormones were statistically significantly associated with sICAM-1 among the placebo group (Table 4) .
Women receiving ET had a significant positive association between CRP and E 1 (P = 0.0003), total E 2 (P G 0.0001), free E 2 (P = 0.001), and SHBG (P = 0.002), adjusted for age and BMI (Table 4 ). A significant inverse association was observed between CRP and DHEA (P = 0.006); the remaining androgens were not associated with CRP. Among women receiving placebo, free E 2 was positively (P = 0.05) associated with CRP, whereas total testosterone and SHBG were inversely associated with CRP (P = 0.03 and 0.004, respectively).
Adjusted for age and BMI, homocysteine was significantly inversely associated with E 1 (P = 0.001), total E 2 (P = 0.0006), and free E 2 (P = 0.0009) in estrogen users ( Table 5 ). None of the androgens or SHBG was significantly associated with homocysteine among women taking ET. No hormone was significantly associated with homocysteine in the placebo group.
Lag time, lag rate, and log rate, three parameters of LDL oxidation kinetics, were not associated with any of the sex hormones in either treatment group (all P values 9 0.10; data not shown). sICAM-1 was significantly positively associated with homocysteine (A estimate, 1.80 [SE, 0.38]; P G 0.0001) but not with LDL oxidation parameters. CRP was not associated with homocysteine or LDL-oxidation lag time (data not shown).
DISCUSSION
Few studies have examined the relationship between sex hormone concentrations and markers of inflammation in post-menopausal women. Most such studies included women not using HT, whereas a few others included HT users. Our population, half taking oral ET and the other half taking placebo, offers the unique opportunity to compare the associations of inflammatory markers with sex hormones at pharmacological and physiological levels. EPAT women using ET had significantly higher levels of estrogens and SHBG and lower levels of androgens, including free testosterone, DHEA, and A4.
The inverse associations between sICAM-1 and estrogens among ET users indicate a beneficial anti-inflammatory effect of estrogens at pharmacological levels. However, lack of such associations in the placebo group indicate that the beneficial anti-inflammatory impact of estrogens can be expected only at higher levels of estrogens as in ET users but not at the endogenous physiological levels of postmenopausal women not using ET. According to a cross-sectional study, postmenopausal women (n = 74) not using HT had 24% higher mean levels of circulating ICAM-1 compared with premenopausal women (n = 60; P G 0.001). 5 Our results support the evidence that inflammatory marker levels rise after menopause because of a sharp decline in estrogen. Our findings also support the results from multiple studies showing favorable effects of HT on soluble markers of vascular inflammation. 6<8,15 In EPAT, ET also significantly reduced plasma sICAM-1 levels. 16 In vivo studies have also demonstrated an inhibitory effect of E 2 on cytokine-induced intercellular adhesion molecule. 17 We did not find any significant associations between endogenous physiological levels of estrogens and sICAM-1 among the postmenopausal women not using ET. Consistent with our finding, a cross-sectional study among a subset of participants (n = 623) from the Postmenopausal Estrogen Progestin Intervention (PEPI) Trial 18 showed no association of endogenous serum levels of total E 2 measured at baseline (before HT initiation) with interleukin 6 (IL-6) and sICAM-1.
These results indicate that physiological levels of estrogen in postmenopausal women are too low to have any beneficial impact on this inflammatory marker. We also found that higher SHBG levels were associated with lower sICAM-1 concentrations in ET users. No such association was observed at the physiological concentration of SHBG. Lower serum SHBG concentrations have consistently been associated with increased risk of atherosclerosis and cardiovascular disease in postmenopausal women. 19<21 We recently reported a significant beneficial impact of SHBG on atherosclerosis progression in the EPAT population. 22 However, the mechanisms involved in the cardioprotective effect of SHBG are largely unknown. Several hypotheses have been proposed, including maintenance of the estrogento-androgen ratio and a direct effect of SHBG on endothelial cellYmediated cyclic adenosine monophosphate. 19 Our analyses showed that a higher SHBG concentration was significantly associated with lower sICAM-1 levels, which may partly explain the cardioprotective effect of SHBG. The molecular mechanism of such an effect remains to be explored.
Among women with physiological sex hormone levels (placebo group), there was a significant inverse relationship between SHBG and CRP, which is consistent with previous reports. 18 ,23<25 On the other hand, pharmacological levels of estrogen (oral ET group) were associated with an increase in CRP level. It is noteworthy that despite a reduction in the levels of other markers of inflammation, such as E-selectin, VCAM, sICAM-1, serum amyloid A, and IL-6, as reported in many studies, oral ET has been consistently associated with an increase in CRP levels and has been attributed to the hepatic first-pass metabolism of E 2 taken orally. 6, 7, 10, 15, 26 Like CRP, SHBG is also produced in the liver, and oral ET has been consistently shown to increase the levels of SHBG, a finding also supported by our study (Table 2) . Therefore, the strong positive associations we found between estrogens/SHBG and CRP among oral ET users could be explained by a first-pass hepatic effect rather than a generalized proinflammatory response. In support of this explanation, CRP was not associated with atherosclerosis progression in EPAT participants. 16 However, our finding of an inverse association of total testosterone and CRP at physiological concentrations among ET nonusers is novel and requires further understanding.
Homocysteine, an intermediate metabolite of methionine, can cause endothelial dysfunction and has been suggested to be a potent inducer of inflammation. 27, 28 Increased levels of homocysteine have been associated with increased IL-6 production from monocytes and can enhance monocyte adhesion to the vascular endothelium by up-regulating VCAMs. 29, 30 Several HT trials have shown that oral estrogen use, alone or combined with progestin, decreased serum homocysteine levels in postmenopausal women. 31<34 Our data support another potential anti-inflammatory property of estrogen showing a significant inverse association between estrogens and homocysteine concentrations. Of note, this beneficial effect of estrogen was observed only at pharmacological levels in women using ET.
Because ET significantly reduced the serum concentrations of all the androgens except for total testosterone in EPAT, we expected that androgens might not show significant associations with markers of inflammation among ET users. However, we did see a significant positive association between free testosterone and sICAM-1 and an inverse association between DHEA and CRP among the ET users. Unlike estrogens, the effect of androgens on markers of inflammation in postmenopausal women has not been frequently studied. A cross-sectional report from the PEPI Trial demonstrated a borderline inverse association between endogenous levels of bioavailable testosterone and sICAM-1 among women not treated with HT. 18 Our results showed no associations between sICAM-1 and any of the androgens at physiological concentrations but a significant positive association between free testosterone and sICAM-1 among ET users. The PEPI substudy also reported a significant positive association between bioavailable testosterone and CRP among postmenopausal women not using HT, a finding supported by the longitudinal study of women in midlife in the Study of Women Across the Nation. 25 In contrast, we found a significant inverse association between CRP and free testosterone at physiological concentrations. A possible explanation for such differences between our study and the PEPI and the Study of Women Across the Nation substudies could be the cross-sectional nature of those latter studies, whereas in the current study, we had multiple assessments of the hormones for 2 years. Although there are reports showing a detrimental effect of testosterone on human vascular endothelial cells 35 and an anti-inflammatory effect of DHEA, 36 we could not explain why we observed the proinflammatory and anti-inflammatory association of testosterone and DHEA, respectively, only at pharmacological levels. Further evaluation of the role of testosterone in vascular inflammation and risk of cardiovascular disease in postmenopausal women is warranted.
The primary results of EPAT showed a significant reduction in the progression of carotid atherosclerosis in women taking oral ET compared with the placebo group. 11 We have also shown in EPAT that serum levels of estrogens, including E 1 , total and free E 2 , and SHBG, were significant inverse correlates of carotid atherosclerosis progression, and these associations were mediated partly by the beneficial effect of estrogens and SHBG on lipids. 22 Results reported in the current study suggest an anti-inflammatory impact of estrogen and SHBG at pharmacological levels. Although oral ETYinduced changes in the inflammatory markers were not associated with subclinical atherosclerosis progression in this group of women, as reported in a previous publication, 16 the results of the current study may have implications for cardiovascular events, including ischemic heart disease and cardiovascular mortality. Evidence shows that soluble adhesion molecules, including sICAM, can predict future death among patients with coronary artery disease. 37 Homocysteine has been linked with ischemic heart disease and stroke. 38 
CONCLUSIONS
In conclusion, our results support the anti-inflammatory effect of estrogens in postmenopausal women as these hormones were inversely associated with sICAM-1 and homocysteine. These results are suggestive of a potential protective role of estrogen on cardiovascular disease. We also report that these anti-inflammatory effects are achieved only at ET-induced pharmacological levels. The positive associations of estrogens and SHBG with CRP at pharmacological levels may not be a proinflammatory effect but rather may be explained by a hepatic first-pass mechanism. However, the underlying mechanism for the inverse association between SHBG and CRP levels at physiological levels needs further attention. Future studies are warranted to understand the impact of androgens on markers of inflammation.
